このページは自動翻訳されたものであり、翻訳の正確性は保証されていません。を参照してください。 英語版 ソーステキスト用。

Alaska Alliance for Community Engagement Phase II: Partnership for Action Toward Health (AK ACE-PATH)

2026年8月30日 更新者:University of Alaska Fairbanks

Alaska Alliance for Community Engagement Phase II: Protecting Health in the American Arctic: Implementing Localized Solutions to Promote Health and Prevent Chronic Disease in Rural Alaska

The AK ACE-PATH Phase II study aims to pilot and implement a novel intervention, Tools for Arctic Health Promotion (TAHP), to address Alaska Native (AN) community priorities related to local health and community-level resilience.

調査の概要

詳細な説明

In Phase I of AK ACE, community partners identified and prioritized local stressors through a consensus-based process. Building on these findings, Phase II will implement interventions targeting the highest-priority stressors through modules designed to improve health outcomes.This study addresses a critical gap in understanding local health and mental health among AN populations facing rapid social change and overlapping public health challenges. The project focuses on developing community-driven solutions to improve physiological and mental health, particularly among youth, and to prevent chronic disease across the lifespan in rural Alaska. To achieve these goals, the study will develop and implement Tools for Arctic Health Promotion (TAHP), a novel intervention integrating data-driven tools and evidence-based community strategies. TAHP will support structured community engagement and deliver manualized health activities to approximately 410 adults and youth across five rural AN communities. The TAHP intervention will be evaluated through a feasibility pilot in one community and a paired dynamic waitlisted design (DWLD) across four additional communities. Behavioral and biological measures will assess individual- and community-level impacts on chronic disease prevention and mental health promotion.

研究の種類

介入

入学 (推定)

360

段階

  • フェーズ 1

連絡先と場所

このセクションには、調査を実施する担当者の連絡先の詳細と、この調査が実施されている場所に関する情報が記載されています。

研究連絡先

研究連絡先のバックアップ

研究場所

    • Alaska
      • Fairbanks、Alaska、アメリカ、99775
        • University of Alaska Fairbanks
        • コンタクト:

参加基準

研究者は、適格基準と呼ばれる特定の説明に適合する人を探します。これらの基準のいくつかの例は、人の一般的な健康状態または以前の治療です。

適格基準

就学可能な年齢

  • 子
  • 大人
  • 高齢者

健康ボランティアの受け入れ

はい

説明

Inclusion Criteria:

  • Self-identify as a permanent resident of the study community
  • Be a youth between the ages of 12-17 years or an adult 18+
  • Be able to provide written informed consent

Exclusion Criteria:

  • Does not have permanent residence in the community or has lived in the community less than 5 years
  • Is unable to provide written informed consent

研究計画

このセクションでは、研究がどのように設計され、研究が何を測定しているかなど、研究計画の詳細を提供します。

研究はどのように設計されていますか?

デザインの詳細

  • 主な目的:防止
  • 割り当て:なし
  • 介入モデル:単一グループの割り当て
  • マスキング:なし(オープンラベル)

武器と介入

参加者グループ / アーム
介入・治療
実験的:Enrollment in TAHP
The study will enroll 360 participants from four unique community settings to receive the TAHP intervention. The study design will make use of a dynamic wait-listed design (DWLD) with 360 participants assessed with behavioral and community-level measures at four time points: baseline (B), intervention midpoint (T1), Intervention end (T2) and 12-month follow-up (T3).
The TAHP intervention will utilize a valid measure of rural AN community-level protective factors (Allen, et al., 2025), and an evidence-based toolkit containing strategies proven to increase mental health and well-being in rural AN communities (Allen, Charles, et al., 2023). A formalized community engaged process will generate new intervention activities that integrate cutting-edge science to address local health priorities.

この研究は何を測定していますか?

主要な結果の測定

結果測定
メジャーの説明
時間枠
Perceived Stress Scale Questionnaire will measure individual-level indicators of stress that we hypothesize will decrease over time with intervention participation
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The NIH Toolbox Perceived Stress Scale is a standardized tool designed to assess how unpredictable, uncontrollable, and overloaded individuals feel in their lives. We will analyze how individual stress indicators are mitigated over time by intervention participation.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
General Life Satisfaction Scale will measure individual level indicators of life satisfaction that we hypothesize will increase with intervention participation
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The NIH Toolbox General Life Satisfaction Scale is a tool designed to assess an individual's cognitive evaluation of their life experiences and overall satisfaction. We will assess how the intervention mitigates life satisfaction with individuals who participate.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if depression decreases with intervention participation using the PHQ-9 Questionnaire
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Patient Health Questionnaire 9 (PHQ-9) measures the frequency of depressed mood and anhedonia over the past two weeks. We will assess how the intervention impacts depressive symptoms with individual participation.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if anxiety symptoms decrease with intervention participation using the GAD-7
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Generalized Anxiety Disorder 7-Item (GAD-7) Screener will be given at every time point to assess how the intervention mitigates anxiety with individual participants
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if food security increases using the food security index from the PhenX Toolkit
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The PhenX Toolkit includes standardized measures for assessing food security, which is crucial for understanding social determinants of health. We will use items from the standardized food security tools to evaluate how food access impacts health outcomes and if food security increases with individual participation in the intervention.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess if cultural efficacy increases with individual intervention participation using the Cultural Efficacy Scale.
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Cultural Efficacy Scale developed by Gonzalez, Sittner, and Walls in 2022 measures individuals' comfort and access to cultural and traditional resources, particularly within Indigenous communities. This scale consists of 7-8 items, each with a range of response options from "strongly disagree" to "strongly agree." We will analyze the data to link cultural efficacy with mental health outcomes (depression and anxiety), highlighting the protective effects of engagement in the intervention.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess how the intervention increases individual protective factors using the Multi-Cultural Mastery Scale
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Multicultural Mastery Scale, developed by Allen and Mohatt, assesses coping strategies through self-mastery and communal mastery dimensions. It includes subscales that differentiate between mastery related to family and friends, highlighting the importance of social networks. We will utilize data from this scale to determine how the intervention increases positive coping and builds social networks connections in individuals who participate.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess how intervention participation increases social and cultural connectedness using the Awareness of Connectedness Scale
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Awareness of Connectedness Scale (ACS), developed by Mohatt and Fok, measures an individual's awareness of their interrelatedness with family, community, and the natural environment. This scale is particularly focused on cultural aspects of wellness and healing among Alaska Native people, providing insights into their social and ecological connections. We will utilize data from the scale to assess the intervention impacts on building connectedness among individual participants.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
We will assess how the intervention increases reasons for life and meaning and purpose using the Reasons for Life Scale
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Reasons for Life Scale (RFL), developed by Allen and Rasmus, focuses on cultural strengths and protective factors against suicide, particularly among Alaska Native people. It emphasizes resilience, cultural teachings, and community recognition as vital components in promoting mental health and preventing suicide. We will utilize data from scale to assess how the intervention promotes reasons for life and associates with mental health outcomes (depression and anxiety) in individuals who participate in activities.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)

二次結果の測定

結果測定
メジャーの説明
時間枠
We will assess the increase in community-level factors that are protective and contribute to health outcomes using the Protective Community Scale
時間枠:Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)
The Protective Community Scale (PCS), developed by Wexler, Allen, and Rasmus, aims to identify community-level protective factors that can reduce suicide risk among Alaska Native youth. This scale is part of a broader effort to enhance resilience in these communities through culturally relevant measures and community engagement. We will analyze data from the PCS to determine if the intervention has mitigated environmental stressors and increased community protection.
Day 1 (baseline), 4 months (T1), 8 months (T2) and at 20 months (T3)

その他の成果指標

結果測定
メジャーの説明
時間枠
We will assess changes to a stress biomarker, cortisol, using Salimetrics OnTimePoint SalivaTM Collection Management application system.
時間枠:Day 1 (baseline), 8 months (T2) and at 20 months (T3)
To measure the impacts of our intervention on biological outcomes, we will assess biomarkers associated with allostatic load - cortisol as an indicator of physiological stress response. These biomarkers will allow us to evaluate whether participation in the intervention is associated with reduced chronic stress burden and improved mental health (anxiety and depression) over time. Our proposed saliva collection protocol will involve our research team members administering the saliva kits with youth and adult participants over a 3-day period with multiple tests to capture cortisol levels throughout the day. Multi-day cortisol levels will be averaged to determine a baseline, and the same process will be used for saliva collection and measurement of cortisol levels at each time point.
Day 1 (baseline), 8 months (T2) and at 20 months (T3)

協力者と研究者

ここでは、この調査に関係する人々や組織を見つけることができます。

出版物と役立つリンク

研究に関する情報を入力する責任者は、自発的にこれらの出版物を提供します。これらは、研究に関連するあらゆるものに関するものである可能性があります。

研究記録日

これらの日付は、ClinicalTrials.gov への研究記録と要約結果の提出の進捗状況を追跡します。研究記録と報告された結果は、国立医学図書館 (NLM) によって審査され、公開 Web サイトに掲載される前に、特定の品質管理基準を満たしていることが確認されます。

主要日程の研究

研究開始 (推定)

2026年9月21日

一次修了 (推定)

2028年10月31日

研究の完了 (推定)

2029年4月30日

試験登録日

最初に提出

2026年8月25日

QC基準を満たした最初の提出物

2026年8月30日

最初の投稿 (実際)

2026年9月3日

学習記録の更新

投稿された最後の更新 (実際)

2026年9月3日

QC基準を満たした最後の更新が送信されました

2026年8月30日

最終確認日

2026年8月1日

詳しくは

本研究に関する用語

個々の参加者データ (IPD) の計画

個々の参加者データ (IPD) を共有する予定はありますか?

いいえ

医薬品およびデバイス情報、研究文書

米国FDA規制医薬品の研究

いいえ

米国FDA規制機器製品の研究

いいえ

この情報は、Web サイト clinicaltrials.gov から変更なしで直接取得したものです。研究の詳細を変更、削除、または更新するリクエストがある場合は、register@clinicaltrials.gov。 までご連絡ください。 clinicaltrials.gov に変更が加えられるとすぐに、ウェブサイトでも自動的に更新されます。

購読する